Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

The phosphatidylinositol 3-kinase (PI3K) pathway is commonly deregulated in cancer. In recent years, the results of the first phase I clinical trials with PI3K inhibitors have become available. In comparison to other targeted agents such v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Brana, Irene, Siu, Lillian L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552942/
https://www.ncbi.nlm.nih.gov/pubmed/23232172
http://dx.doi.org/10.1186/1741-7015-10-161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552942/
https://www.ncbi.nlm.nih.gov/pubmed/23232172
http://dx.doi.org/10.1186/1741-7015-10-161

Ejemplares similares